PE20160681A1 - Formulacion de premezcla de dexmedetomidina - Google Patents
Formulacion de premezcla de dexmedetomidinaInfo
- Publication number
- PE20160681A1 PE20160681A1 PE2016000713A PE2016000713A PE20160681A1 PE 20160681 A1 PE20160681 A1 PE 20160681A1 PE 2016000713 A PE2016000713 A PE 2016000713A PE 2016000713 A PE2016000713 A PE 2016000713A PE 20160681 A1 PE20160681 A1 PE 20160681A1
- Authority
- PE
- Peru
- Prior art keywords
- dexmedetomidine
- premix formulation
- dexmedetomidine premix
- composition
- sedation
- Prior art date
Links
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 title abstract 2
- 229960004253 dexmedetomidine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 206010039897 Sedation Diseases 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 239000011521 glass Substances 0.000 abstract 1
- -1 hydrochloride Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000036280 sedation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Se refiere a una composicion farmaceutica liquida que comprende dexmedetomidina o una sal farmaceuticamente aceptable, tal como clorhidrato, a una concentracion de 0.005 a 50 ug/mL, en donde la composicion se dispone dentro de un contenedor de vidrio sellado como una premezcla que no requiere dilucion antes de la administracion; siendo util en el cuidado perioperativo de un paciente o para la sedacion
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/343,672 US8242158B1 (en) | 2012-01-04 | 2012-01-04 | Dexmedetomidine premix formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160681A1 true PE20160681A1 (es) | 2016-07-28 |
Family
ID=46613447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000713A PE20160681A1 (es) | 2012-01-04 | 2012-06-18 | Formulacion de premezcla de dexmedetomidina |
| PE2013000622A PE20131166A1 (es) | 2012-01-04 | 2012-06-18 | Formulacion de premezcla de dexmedetomidina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000622A PE20131166A1 (es) | 2012-01-04 | 2012-06-18 | Formulacion de premezcla de dexmedetomidina |
Country Status (36)
| Country | Link |
|---|---|
| US (10) | US8242158B1 (es) |
| EP (2) | EP2648520B1 (es) |
| JP (4) | JP5892177B2 (es) |
| KR (1) | KR101632103B1 (es) |
| CN (2) | CN107802624A (es) |
| AR (2) | AR089673A1 (es) |
| AU (1) | AU2013201069B1 (es) |
| BR (1) | BR112013008005A8 (es) |
| CA (1) | CA2806706C (es) |
| CL (1) | CL2013000815A1 (es) |
| CO (1) | CO6680698A2 (es) |
| CY (1) | CY1120521T1 (es) |
| DK (1) | DK2648520T3 (es) |
| EC (1) | ECSP13012569A (es) |
| ES (1) | ES2671749T3 (es) |
| GT (1) | GT201300055A (es) |
| HK (1) | HK1249429A1 (es) |
| HR (1) | HRP20180838T1 (es) |
| HU (1) | HUE038128T2 (es) |
| IL (1) | IL224867B (es) |
| LT (1) | LT2648520T (es) |
| MX (2) | MX375001B (es) |
| MY (2) | MY188598A (es) |
| PE (2) | PE20160681A1 (es) |
| PH (1) | PH12013500372A1 (es) |
| PL (1) | PL2648520T3 (es) |
| PT (1) | PT2648520T (es) |
| RS (1) | RS57346B1 (es) |
| SA (2) | SA115360458B1 (es) |
| SG (1) | SG191706A1 (es) |
| SI (1) | SI2648520T1 (es) |
| TR (1) | TR201809123T4 (es) |
| TW (2) | TWI593409B (es) |
| UY (1) | UY34562A (es) |
| WO (1) | WO2013103378A1 (es) |
| ZA (1) | ZA201301649B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130096170A1 (en) | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
| US8242158B1 (en) * | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
| ES2847936T3 (es) * | 2013-10-07 | 2021-08-04 | Teikoku Pharma Usa Inc | Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina |
| ES2856189T3 (es) | 2013-10-07 | 2021-09-27 | Teikoku Pharma Usa Inc | Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina |
| CN105682650B (zh) * | 2013-10-07 | 2020-09-25 | 帝国制药美国公司 | 用于使用非镇静性右旋美托咪啶经皮组合物治疗戒断综合征的方法和组合物 |
| KR101827980B1 (ko) | 2013-10-07 | 2018-02-13 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법 |
| EP3082427A4 (en) * | 2013-12-18 | 2017-08-02 | Gnt Llc | Compositions and methods for treatment of glaucoma |
| FI127534B (en) * | 2014-11-10 | 2018-08-31 | Vetcare Oy | Substituted benzoefuroquinolizine and ɑ2-adrenergic agonist comprising compositions |
| CN106038538A (zh) * | 2015-04-17 | 2016-10-26 | 江苏恒瑞医药股份有限公司 | 一种右美托咪定的预混合制剂 |
| CN105168122B (zh) * | 2015-09-24 | 2018-11-27 | 辰欣药业股份有限公司 | 一种盐酸右美托咪定注射液及其制备工艺 |
| US20170128421A1 (en) * | 2015-11-11 | 2017-05-11 | Siva Prasad Reddy Sura | Premix formulation for parenteral use and packaging thereof |
| US10632043B2 (en) * | 2015-11-11 | 2020-04-28 | Aurobindo Pharma Ltd | Premix formulation for parenteral use and packaging thereof |
| US9717796B1 (en) * | 2016-04-20 | 2017-08-01 | Slypharma, Llc | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
| CN107412152B (zh) * | 2016-05-24 | 2020-12-04 | 海南合瑞制药股份有限公司 | 一种盐酸右美托咪定注射液组合物 |
| ES2895764T3 (es) * | 2016-12-26 | 2022-02-22 | Hisamitsu Pharmaceutical Co | Dispositivo de microagujas |
| EP4368169A3 (en) | 2016-12-31 | 2024-08-07 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| CN107028880A (zh) * | 2017-06-09 | 2017-08-11 | 安徽赛诺制药有限公司 | 一种盐酸右美托咪定注射液的生产工艺 |
| WO2019164765A1 (en) * | 2018-02-26 | 2019-08-29 | Slayback Pharma Llc | Ready-to-use dexmedetomidine compositions |
| CN108956809B (zh) * | 2018-06-04 | 2021-03-23 | 四川科伦药物研究院有限公司 | 一种检测1-(1-氯乙基)-2,3-二甲苯有关物质的方法 |
| CN112351809B (zh) | 2018-06-26 | 2023-07-14 | 久光制药株式会社 | 微针装置及其制造方法 |
| US20210267944A1 (en) | 2018-06-27 | 2021-09-02 | Bioxcel Therapeutics, Inc. | Methods for treating agitation using dexmedetomidine hydrochloride |
| MX2020014000A (es) | 2018-06-27 | 2021-06-15 | Bioxcel Therapeutics Inc | Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. |
| CN108872431B (zh) * | 2018-07-09 | 2021-03-23 | 成都倍特药业股份有限公司 | 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法 |
| CN109081811A (zh) * | 2018-09-19 | 2018-12-25 | 南京正大天晴制药有限公司 | 盐酸右美托咪定的有关物质及其制备方法 |
| JP2019048091A (ja) * | 2018-10-23 | 2019-03-28 | ニプロ株式会社 | デクスメデトミジン注射液を充填したプレフィルドシリンジ |
| US11160791B2 (en) | 2018-11-01 | 2021-11-02 | Medefil, Inc. | Dexmedetomidine injection premix formulation in ready to use (RTU) bags |
| CN111481506B (zh) * | 2019-01-25 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种包含经鼻给药的右美托咪定组合物的药物制品 |
| WO2020176807A1 (en) | 2019-02-27 | 2020-09-03 | Vanderbilt University | Methods of treating trigeminal nerve pain |
| CN116474218A (zh) * | 2019-06-28 | 2023-07-25 | 四川普锐特药业有限公司 | 保持给药均一度的药物流体分配器及右美托咪定鼻喷器 |
| AU2020316013A1 (en) * | 2019-07-19 | 2022-02-17 | Arx, Llc | Non-sedating dexmedetomidine treatment regimens |
| EP4225305A4 (en) * | 2020-10-08 | 2024-10-23 | Bioxcel Therapeutics, Inc. | TREATMENT OF BIPOLAR DISEASES AND PSYCHOSES WITH DEXMEDETOMIDINE HYDROCHLORIDE |
| EP4085891A1 (en) | 2021-05-05 | 2022-11-09 | B. Braun Melsungen AG | Dexmedetomidine-solution in a low-density polyethylene container |
| CN113041242A (zh) * | 2021-05-18 | 2021-06-29 | 上海交通大学医学院附属仁济医院 | 右美托咪定在促进肝脏再生中的应用 |
| CN113116815A (zh) * | 2021-06-07 | 2021-07-16 | 辰欣药业股份有限公司 | 一种盐酸右美托咪定注射液的制备方法 |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| JPS6058890A (ja) | 1983-09-13 | 1985-04-05 | Mizusawa Ind Chem Ltd | 感熱記録紙用填剤 |
| FI844786A0 (fi) | 1984-12-04 | 1984-12-04 | Farmos Oy | Terapeutiskt utnyttjbar foerening. |
| GB2206880B (en) | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
| US5344840A (en) | 1988-02-29 | 1994-09-06 | Orion-Yhtyma Oy | 4-substituted imidazole derivatives useful in perioperative care |
| US5217718A (en) | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| US5124157A (en) | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| FI894911A0 (fi) | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| US5304569A (en) | 1989-11-13 | 1994-04-19 | Orion-Yhtyma Oy | Compositions and their use in lowering intraocular pressure |
| ES2107537T3 (es) | 1991-04-25 | 1997-12-01 | Univ Brown Res Found | Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados. |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| ES2179831T3 (es) | 1992-09-29 | 2003-02-01 | Inhale Therapeutic Syst | Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana. |
| GB2281206A (en) | 1993-08-25 | 1995-03-01 | Orion Yhtymae Oy | Use of dexmedetomidine |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| CA2196922C (fr) * | 1994-08-08 | 2004-06-01 | Houssam Ibrahim | Preparation pharmaceutiquement stable d'oxaliplatine |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| DE19749724A1 (de) | 1997-11-11 | 1999-06-10 | Gruenenthal Gmbh | Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln |
| US6716867B1 (en) | 1998-04-01 | 2004-04-06 | Orion Corporation | Use of dexmedetomidine for ICU sedation |
| AR015744A1 (es) * | 1998-04-01 | 2001-05-16 | Orion Corp | Uso de dexmedetomidina para sedacion en terapia intensiva |
| PE20001396A1 (es) | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista |
| EP1121933A1 (en) | 2000-02-02 | 2001-08-08 | Pfizer Products Inc. | Premixed alatrofloxacin injectable compositions |
| US6310094B1 (en) | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| EP1372637B1 (en) | 2001-03-29 | 2008-02-20 | Baxter International Inc. | Premixed amiodarone parenteral solution and method for making the same |
| US6806291B1 (en) * | 2003-10-09 | 2004-10-19 | The Foundation For The Lsu Health Sciences Center | Analgesic compounds, their synthesis and pharmaceutical compositions containing them |
| BRPI0604377A (pt) | 2006-10-27 | 2008-06-24 | Cristalia Prod Quimicos Farm | microemulsão óleo/água de propofol estável e pronta-para-uso |
| US20080308444A1 (en) * | 2007-06-13 | 2008-12-18 | Baxter International Inc. | Packaging system and method of alerting a practitioner |
| WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
| US20100197694A1 (en) | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
| EP2165706A1 (en) | 2008-09-18 | 2010-03-24 | BioAlliance Pharma | Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers. |
| US8100890B2 (en) * | 2008-10-15 | 2012-01-24 | Bioquiddity, Inc. | Special purpose fluid dispenser with pre-filled reservoir |
| EP2363147B1 (en) | 2008-10-30 | 2016-02-24 | National University Corporation Okayama University | Composition for local anesthesia |
| NZ596976A (en) | 2009-05-15 | 2014-05-30 | Recro Pharma Inc | Sublingual dexmedetomidine compositions and methods of use thereof |
| US8410140B2 (en) * | 2009-06-01 | 2013-04-02 | The Regents Of The University Of Michigan | Anesthetic methods and compositions |
| WO2011016049A2 (en) | 2009-07-31 | 2011-02-10 | Astron Research Limited | A stable composition of ready-to-use gemcitabine injection |
| WO2011075621A1 (en) | 2009-12-17 | 2011-06-23 | Alpha Synergy Development, Inc. | Compositions and methods for ophthalmic delivery of nasal decongestants |
| FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
| US20130096170A1 (en) | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
| US8242158B1 (en) | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
-
2012
- 2012-01-04 US US13/343,672 patent/US8242158B1/en active Active
- 2012-06-18 MY MYPI2017000279A patent/MY188598A/en unknown
- 2012-06-18 JP JP2013552744A patent/JP5892177B2/ja active Active
- 2012-06-18 PL PL12823234T patent/PL2648520T3/pl unknown
- 2012-06-18 HR HRP20180838TT patent/HRP20180838T1/hr unknown
- 2012-06-18 CA CA2806706A patent/CA2806706C/en active Active
- 2012-06-18 TR TR2018/09123T patent/TR201809123T4/tr unknown
- 2012-06-18 PE PE2016000713A patent/PE20160681A1/es unknown
- 2012-06-18 BR BR112013008005A patent/BR112013008005A8/pt not_active Application Discontinuation
- 2012-06-18 EP EP12823234.5A patent/EP2648520B1/en not_active Revoked
- 2012-06-18 ES ES12823234.5T patent/ES2671749T3/es active Active
- 2012-06-18 WO PCT/US2012/042940 patent/WO2013103378A1/en not_active Ceased
- 2012-06-18 KR KR1020137007434A patent/KR101632103B1/ko active Active
- 2012-06-18 PT PT128232345T patent/PT2648520T/pt unknown
- 2012-06-18 EP EP18157214.0A patent/EP3345599A1/en not_active Withdrawn
- 2012-06-18 PH PH1/2013/500372A patent/PH12013500372A1/en unknown
- 2012-06-18 LT LTEP12823234.5T patent/LT2648520T/lt unknown
- 2012-06-18 CN CN201710644232.4A patent/CN107802624A/zh active Pending
- 2012-06-18 HU HUE12823234A patent/HUE038128T2/hu unknown
- 2012-06-18 AU AU2013201069A patent/AU2013201069B1/en active Active
- 2012-06-18 RS RS20180628A patent/RS57346B1/sr unknown
- 2012-06-18 PE PE2013000622A patent/PE20131166A1/es not_active Application Discontinuation
- 2012-06-18 MX MX2017014041A patent/MX375001B/es unknown
- 2012-06-18 MY MYPI2013000733A patent/MY161022A/en unknown
- 2012-06-18 DK DK12823234.5T patent/DK2648520T3/en active
- 2012-06-18 MX MX2013003629A patent/MX2013003629A/es unknown
- 2012-06-18 SG SG2013015441A patent/SG191706A1/en unknown
- 2012-06-18 SI SI201231312T patent/SI2648520T1/en unknown
- 2012-06-18 CN CN2012800037344A patent/CN103281902A/zh active Pending
- 2012-07-03 US US13/541,524 patent/US8338470B1/en active Active
- 2012-11-15 US US13/678,260 patent/US8436033B1/en active Active
- 2012-11-15 US US13/678,148 patent/US8455527B1/en active Active
-
2013
- 2013-01-04 TW TW105101909A patent/TWI593409B/zh active
- 2013-01-04 AR ARP130100046A patent/AR089673A1/es not_active Application Discontinuation
- 2013-01-04 UY UY0001034562A patent/UY34562A/es not_active Application Discontinuation
- 2013-01-04 TW TW102100340A patent/TWI574688B/zh active
- 2013-01-05 SA SA115360458A patent/SA115360458B1/ar unknown
- 2013-01-05 SA SA113340176A patent/SA113340176B1/ar unknown
- 2013-02-21 IL IL224867A patent/IL224867B/en active IP Right Grant
- 2013-02-27 GT GT201300055A patent/GT201300055A/es unknown
- 2013-03-04 ZA ZA2013/01649A patent/ZA201301649B/en unknown
- 2013-03-06 CO CO13045125A patent/CO6680698A2/es unknown
- 2013-03-22 CL CL2013000815A patent/CL2013000815A1/es unknown
- 2013-04-19 EC ECSP13012569 patent/ECSP13012569A/es unknown
- 2013-04-22 US US13/867,861 patent/US8648106B2/en active Active
- 2013-11-12 HK HK18109069.7A patent/HK1249429A1/en unknown
- 2013-12-27 JP JP2013273409A patent/JP5990832B2/ja active Active
-
2014
- 2014-01-24 JP JP2014011233A patent/JP5927680B2/ja active Active
- 2014-02-10 US US14/177,008 patent/US9320712B2/en active Active
-
2015
- 2015-02-06 JP JP2015022203A patent/JP2015110639A/ja not_active Withdrawn
-
2016
- 2016-03-02 US US15/058,602 patent/US9616049B2/en active Active
-
2017
- 2017-02-28 US US15/444,932 patent/US10016396B2/en active Active
-
2018
- 2018-05-03 CY CY20181100462T patent/CY1120521T1/el unknown
- 2018-06-08 US US16/003,894 patent/US20180289674A1/en not_active Abandoned
- 2018-06-08 US US16/003,850 patent/US20180289673A1/en not_active Abandoned
-
2019
- 2019-11-06 AR ARP190103245A patent/AR117001A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
| PH12014502778A1 (en) | Antibody formulation | |
| EA201492021A1 (ru) | Антительный состав | |
| UA124922C2 (uk) | Модулятори ядерного транспорту та їх застосування | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| DOP2015000170A (es) | Compuestos químicos | |
| AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| UA110979C2 (uk) | Рідка фармацевтична композиція, яка включає нітизинон | |
| MX2014009660A (es) | Formulacion de anticuerpo anti-selectina p. | |
| EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| BR112014031306A2 (pt) | composição farmacêutica e respectivos usos | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| PE20160198A1 (es) | Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas | |
| EA201500128A1 (ru) | Педиатрические жидкие композиции для перорального введения, содержащие непадутант | |
| EA201590732A1 (ru) | Диспергируемая таблетка | |
| EA201500366A1 (ru) | Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора | |
| NZ705340A (en) | Amine salt and crystals thereof | |
| PE20141472A1 (es) | Composicion farmaceutica que comprende cloruro de isometamidium en solucion para el tratamiento de la tripanosomiasis en animales | |
| UA72334U (uk) | Фармацевтичний склад для приготування розчину для парентерального введення людині |